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Abstract
Objective Gabapentin is being investigated as a potential
treatment for occasional disturbed sleep. This study
assessed the pharmacokinetics and tolerability of gaba-
pentin 500 mg and the commonly prescribed sedative/
hypnotic zolpidem tartrate 10 mg, administered separately
and in combination.
Methods Forty healthy participants (19 male, 21 female)
were randomized into this three-period crossover study
[mean (range) age 34.1 (18–45) years, weight 68.3
(51.4–92.7) kg; 60 % white]. Participants were dosed with
gabapentin alone (n = 39), zolpidem tartrate alone
(n = 38), and the combination (gabapentin ? zolpidem)
(n = 38) over three treatment periods, which were sepa-
rated by C7 days. Blood samples were collected pre-dose
and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24 and 36 h post-
dose. Plasma concentrations of each drug were assayed
using validated methods. Pharmacokinetic parameters were
estimated from plasma concentration–time data using
standard non-compartmental methods.
Results For gabapentin ? zolpidem combination versus
gabapentin alone, mean pharmacokinetic parameters were
peak plasma concentration (Cmax) 4.61 versus 4.72 lg/mL,
time to Cmax (tmax) 4.63 versus 3.64 h and the area under
plasma concentration–time curve extrapolated to infinity
(AUC0–?) 53.4 versus 51.0 lg h/mL. For the combination
versus zolpidem alone, mean pharmacokinetic parameters
were Cmax 154 versus 138 ng/mL, tmax 1.45 versus 1.84 h
and AUC0–? 912 versus 854 ng h/mL. The 90 % confi-
dence intervals for Cmax (rate of absorption) and AUC0–?
(extent of absorption) comparing the combination versus
single drug administration fell within the 80–125 % range
accepted for bioequivalence. All treatments were well
tolerated.
Conclusion The pharmacokinetics of gabapentin 500 mg
and zolpidem tartrate 10 mg are unaffected when both
drugs are taken simultaneously, compared with each drug
taken alone.
Key Points
1. This bioequivalence study demonstrates that the
pharmacokinetic properties of gabapentin 500 mg
and zolpidem tartrate 10 mg are unaffected when
both treatments are taken simultaneously, compared
with each drug taken alone, in healthy participants.
2. Both treatments were well tolerated when taken
alone and in combination, in a population of healthy
participants.
1 Introduction
Gabapentin was first developed to treat seizure disorders
and neuropathic pain, and is now being investigated as a
potential sleep aid for occasional disturbed sleep. Studies
suggest that low-dose gabapentin (250 mg [1, 2] and
500 mg [2]) can improve objective and subjective mea-
sures of sleep in adults using a model of occasional
L. A. Galitz
Phase-1 Solutions, Miami Gardens, FL, USA
S. Jayawardena  S. A. Furey (&)
Pfizer Consumer Healthcare, Pfizer Inc, 1 Giralda Farms,
Madison, NJ 07940, USA
e-mail: Sandy.A.Furey@pfizer.com
Drugs R D (2015) 15:71–77
DOI 10.1007/s40268-014-0079-z
disturbed sleep [1, 2]. The exact mechanism by which
gabapentin improves sleep is unknown, but is likely related
to its well-characterized binding affinity to the a2d subunit
of voltage-activated calcium channels, and subsequent
modulatory effects on neurotransmitter release [3, 4]. The
pharmacokinetic profile of gabapentin as an immediate-
release formulation has been well defined across the ther-
apeutic dose range (300–1,800 mg/day, with a recom-
mended dose of 900–1,800 mg/day for approved
indications). For example, after single-dose oral adminis-
tration (300 or 600 mg) [5–7], gabapentin reaches peak
plasma concentration (Cmax) in 2–3 h [time to reach Cmax
(tmax)] [5, 8], and with multiple dosing, achieves steady
state within 24–48 h [8]. Plasma concentrations of gaba-
pentin do not increase proportionally with increasing doses
owing to absorption in only a limited segment of the small
intestine. Gabapentin is eliminated unchanged through the
kidney, with a terminal half-life (t) of 5–7 h [8]. Gaba-
pentin is largely unaffected by alteration in hepatic func-
tion or cytochrome P450 (CYP450) activity [6, 9], and
there are few known drug–drug interactions, including no
interaction observed with other antiepileptic drugs (lamo-
trigine, vigabatrin or oxcarbazepine) [10] or with a con-
traceptive regimen of norethindrone acetate and ethinyl
estradiol [11]. The most common adverse events (AEs)
observed following treatment with gabapentin
(900–1,800 mg/day) (not seen at an equivalent frequency
among placebo-treated patients) were dizziness, somno-
lence and peripheral edema in adults with post-herpetic
neuralgia, and somnolence, dizziness, ataxia, fatigue and
nystagmus in adults with partial seizures with and without
secondary generalization [12]. Gabapentin’s overall phar-
macokinetic and pharmacodynamic profile makes for a
predictable and well-tolerated drug.
There is potential for individuals with sleep disturbances
to self-medicate with multiple sleep products. Zolpidem, an
imidazopyridine agent, is widely prescribed for the short-
term management of insomnia [13]. Zolpidem demonstrates
preferential affinity for GABAA receptors containing the a1
subunit [14]. It is absorbed rapidly, with bioavailability of
70 %, and reaches Cmax in\1 h [15]. Zolpidem shows linear
pharmacokinetics across the 5 to 20-mg therapeutic dose
range. In addition, zolpidem is rapidly metabolized before
being eliminated primarily in bile, urine and feces [15, 16].
Because metabolism occurs via successive CYP450
enzymes, zolpidem has a high potential for drug–drug
interactions with agents that inhibit or induce CYP450
enzymes. Although gabapentin is not metabolized via the
CYP450 pathway [17], there is potential for co-administra-
tion with gabapentin, and therefore, any potential effects of
zolpidem on the pharmacokinetic properties of gabapentin,
and vice versa, warrant investigation. The aim of this study
was to evaluate a potential drug–drug interaction of
gabapentin with zolpidem in healthy participants, when
administered individually and in combination.
2 Methods
2.1 Study Design
Participants were randomized in an open-label, three-per-
iod crossover design to single-dose gabapentin (500 mg),
zolpidem tartrate (10 mg), and the combination (gabapen-
tin 500 mg ? zolpidem tartrate 10 mg), between Novem-
ber 5 and 21, 2001. There was a minimum of 7 days
between treatment periods. Eligibility was determined at
screening. Blood and urine tests were conducted and ana-
lyzed at screening and at each visit. The study was con-
ducted in compliance with the Declaration of Helsinki and
the International Conference on Harmonisation Good
Clinical Practice Guidelines. Protocol, consent documents
and protocol amendments were all approved by the rele-
vant institutional review board at participating centers. The
study is not registered on http://clinicaltrials.gov.
2.2 Participants
All participants provided written, informed consent prior to
randomization. Healthy men and women (of non-child-
bearing potential or those using an acceptable contracep-
tive) aged C18 years and weighing 50–100 kg
(110–220 lbs) were recruited. Participants were considered
healthy if they had no clinically relevant abnormalities on
physical examination. Standard exclusion criteria were
imposed, including, but not limited to, participants with a
known sensitivity to either drug; a positive pregnancy test
on screening; a history of drug or alcohol abuse; or on
physical examination, any clinically significant disease or
abnormality that was deemed likely to affect the properties
of either drug under investigation.
2.3 Analysis of Plasma Samples
Venous blood (210 mL per participant) was collected in
heparinized collection tubes pre-dose (0 h) and at 0.5, 1,
1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24 and 36 h post-dose. Samples
were centrifuged and the plasma stored in labeled, screw-
capped, polypropylene tubes at -20 C within 1 h of
collection. Gabapentin plasma concentrations were deter-
mined by validated liquid chromatography tandem mass
spectrometry methods using 1-(amino-methyl)-cyclohep-
taneacetic acid (PD0403609-0000) as an internal standard
(BioAssay Laboratories, Houston, TX, USA). The analyt-
ical range for detection of gabapentin was 0.025–10.0 lg/
mL, with precision [% coefficient of variation (CV)]
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B15.5 % and accuracy [% relative error (RE)] of
0.2–6.7 %. Zolpidem plasma concentrations were deter-
mined by a validated high-throughput liquid chromatog-
raphy (HPLC) with fluorescence detection, using trazodone
as an internal standard (Covance Laboratories, Inc., Mad-
ison, WI, USA). The analytical range of detection for
zolpidem was 1.00–400 ng/mL, with precision (% CV)
B14 % and accuracy (% RE) of 2.0–5.0 %.
2.4 Pharmacokinetic Parameters
Non-compartmental methods were employed to estimate
pharmacokinetic parameters. The Cmax and tmax were
observed directly from the plasma concentration–time pro-
file of each participant. The area under the concentration–
time curve from time zero to time of last quantifiable con-
centration (tlqc) (AUC0–tlqc) was evaluated using the linear
trapezoidal method. The area was extrapolated to infinity,
AUC0–?, using standard methods. The t was calculated
using the terminal rate constant determined from the terminal
log-linear phase of the concentration–time profile. Pharma-
cokinetic analyses were carried out using WinNonlin
software Pro Version 2.1. Quality control samples were used
in each analytical run to ensure data quality. Data were
reviewed and accepted by quality-control specialists before
being used for pharmacokinetic analyses.
2.5 Safety and Tolerability
All randomized participants were evaluated for safety.
Safety evaluations were conducted throughout the study
and included monitoring of AEs, vital signs, 12-lead
electrocardiograms, and physical examination including
blood pressure, respiratory, and pulse rate. Laboratory tests
were conducted at screening only.
2.6 Statistical Analyses
A sample size of 36 participants completing the study was
estimated on the basis of estimates of intra-subject CV for
zolpidem 10 mg, which is larger than that for gabapentin [18,
19]. The sample size provided at least 80 % power to dem-
onstrate bioequivalence with respect to AUC0–? and Cmax,
assuming a CV of 33 % and no underlying difference
between the combination and each drug administered alone.
Pharmacokinetic analyses were based on participants
who completed each treatment period. Log-transformed
AUC0–? and Cmax were analyzed using analysis of vari-
ance (ANOVA) with treatment sequence, period and
treatment as fixed effects and subject-within-sequence as a
random effect. Results from the ANOVA were used to
calculate 90 % confidence intervals (CIs) for the ratios
(test/reference) of least-squares mean treatment values,
where administration of gabapentin and zolpidem together
was the test treatment and administration of gabapentin
alone and zolpidem alone were the reference treatments.
Lack of an interaction was concluded if the estimated 90 %
CIs for the ratios (test/reference) of adjusted means for




Forty participants were enrolled and randomized. Thirty-six
participants completed the study with no protocol deviations.
Three participants were withdrawn because of positive urine
drug screens (one prior to the second treatment period and
two prior to the third treatment period), and one participant
did not return for the third treatment period. Because of these
withdrawals, 39 participants received gabapentin (500 mg),
38 received zolpidem tartrate (10 mg), and 38 received the
combination and were included in the pharmacokinetic
analyses (Table 1). During the study, no participant took or
received concomitant therapy that was judged to have the
potential to affect pharmacokinetic parameters.
3.2 Pharmacokinetic Analyses
The mean plasma concentration–time profiles for gabapentin
and zolpidem following administration alone or in combi-
nation are shown in Figs. 1 and 2, respectively. For gaba-
pentin ? zolpidem combination versus gabapentin alone,
the mean pharmacokinetic parameters were Cmax 4.61 versus
4.72 lg/mL, tmax 4.63 versus 3.64 h and AUC0–? 53.4
versus 51.0 lg h/mL (Table 2). The 90 % CIs for the
treatment ratio of Cmax (92.0–102.0) and AUC0–?
(99.0–109.0) for the combination versus gabapentin alone
were within the 80–125 % range accepted for bioequiva-
lence (Table 2). For the combination versus zolpidem alone,
the mean pharmacokinetic parameters were Cmax 154.0
versus 138.0 ng/mL, tmax 1.45 versus 1.84 h and AUC0–?
912.0 versus 854.0 ng h/mL (Table 3). The 90 % CIs for the
treatment ratio of Cmax (104.0–118.0) and AUC0–?
(98.1–112.0) for the combination versus zolpidem alone
were within the 80–125 % range accepted for bioequiva-
lence (Table 3). The t of gabapentin or zolpidem was also
similar when administered alone versus in combination, and
averaged *5.5 h for gabapentin and 3.4 h for zolpidem.
3.3 Safety and Tolerability
Co-administration of gabapentin and zolpidem was well
tolerated. Five participants reported seven treatment-
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emergent AEs; all were mild in severity (Table 4). No
deaths, serious or severe AEs, or discontinuations due to
AEs were reported. In addition, no clinically significant
changes in vital signs were recorded pre- versus post-study.
4 Discussion
Gabapentin is being investigated as a potential sleep aid for
occasional disturbed sleep on the basis of clinical evidence
from healthy volunteers and patients with insomnia [1, 2,
20–23]. The present study demonstrated that the pharma-
cokinetics of gabapentin (500 mg) and a commonly pre-
scribed prescription sleep aid, zolpidem tartrate (10 mg),
were unaffected when both drugs were administered
simultaneously, compared with each drug taken alone. In
addition, both drugs at the doses stated were well tolerated
when taken alone or in combination in this group of healthy
individuals.
Zolpidem is widely prescribed in clinical practice for
short-term management of insomnia, and is generally safe
and well tolerated [24, 25]. Although not recommended,
the nature of occasional sleep disturbance may result in
individuals self-medicating with multiple sleep aids to
improve sleep [26, 27]. Of concern, many prescription
sleep aids are associated with significant residual next-day
effects due to long half-lives [28], which could be further
prolonged with a change to the pharmacokinetic elimina-
tion parameters. Our data demonstrate that administration
of gabapentin with zolpidem was bioequivalent to admin-
istration of gabapentin alone, as the 90 % CIs for Cmax
(rate of absorption) and AUC0–? (extent of absorption)
comparing single drug administration versus each drug
administered in combination were within the 80–125 %
range accepted for bioequivalence. Bioequivalence was
also achieved for administration of zolpidem with gaba-
pentin versus zolpidem alone. In addition, administration
of gabapentin or zolpidem alone or in combination did not
change the t for either drug. Therefore, no prolonging of
next-day effects of zolpidem would be expected, although
pharmacodynamic studies would be needed to confirm this
assumption. Overall, our study found no new safety signals
for single-dose use of these two drugs when co-
administered.
Our observations also support what is known about the
pharmacokinetic properties of both drugs, as drug–drug
interactions would not be expected between gabapentin and
zolpidem. For example, zolpidem is metabolized via
CYP3A4, and acts as a mild mechanism-based inactivator
of human CYP3A in vitro [29, 30]. In contrast, gabapentin
is non-metabolized and is eliminated renally primarily as
unchanged drug, showing plasma clearance that is pro-
portional to creatinine clearance [6]. It should be noted that
Table 1 Demographic characteristics of randomized participants at
baseline (n = 40)
Characteristic Number (%) or
mean ± standard deviationa
Male:female 19:21




Black, non-Hispanic 7 (18)
Other 9 (23)
Weight (kg) 68.3 ± 9.7
Range 51.4–92.7
Body mass index (kg/m2) 25.4 ± 2.7
Range 20.7–32.1
a Unless otherwise specified
Fig. 1 Mean gabapentin plasma concentration–time profiles follow-
ing administration of gabapentin alone and with zolpidem tartrate
Fig. 2 Mean zolpidem plasma concentration–time profiles following
administration of zolpidem tartrate alone and with gabapentin
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Table 2 Summary of pharmacokinetic parameters for gabapentin co-administered with zolpidem tartrate (test) and for gabapentin alone
(reference)






90 % Confidence intervala
Lower Upper
n 38 38
Cmax (lg/mL) 4.61 (1.11) 4.72 (1.18) 97.0 92.0 102.0
AUC0–tlqc (lg h/mL) 52.5 (12.6) 50.2 (12.1) 104.0 98.8 109.0
AUC0–? (lg h/mL) 53.4 (12.9) 51.0 (12.4) 104.0 99.0 109.0
tmax (h) 4.63 (1.95) 3.64 (1.17) – – –
t (h) 5.47 (1.06) 5.49 (0.86) – – –
AUC area under the concentration–time curve, Cmax peak plasma concentration, SD standard deviation, t terminal half-life, tlqc time of last
quantifiable concentration, tmax time to peak plasma concentration
a Ratio of mean values, and the confidence interval for the ratio expressed as percentage, based on the model fitted to natural log-transformed
data










90 % Confidence intervala
Lower Upper
n 38 37
Cmax (ng/mL) 154 (49.9) 138 (43.9) 111.0 104.0 118.0
AUC0–tlqc (ng h/mL) 898 (381) 842 (338) 105.0 98.0 112.0
AUC0–? (ng h/mL) 912 (386) 854 (341) 105.0 98.1 112.0
tmax (h) 1.45 (0.94) 1.84 (1.23) – – –
t (h) 3.47 (1.17) 3.44 (1.21) – – –
AUC area under the concentration–time curve, Cmax peak plasma concentration, SD standard deviation, t terminal half-life, tlqc time of last
quantifiable concentration, tmax time to peak plasma concentration
a Ratio of mean values, and the confidence interval for the ratio expressed as percentage, based on the model fitted to natural log-transformed
data
Table 4 Summary and






a Considered by the
investigator to be related to
treatment
Gabapentin Zolpidem Gabapentin ? zolpidem
Evaluable participants 39 38 38
Participants [n (%)] reporting AEs 1 (2.6) 3 (7.9) 1 (2.6)
Participants [n (%)] withdrawing due to AEs 0 (0) 0 (0) 0 (0)
Participants [n (%)] with treatment-related AEsa 1 (2.6) 3 (7.9) 1 (2.6)
Number of AEs 1 4 2
Number of serious AEs 0 0 0
Number of AEs by intensity
Mild 1 4 2
Moderate/severe 0 0 0
Participants (n) reporting AE (by type)
Dizziness 0 1 1
Headache 1 1 0
Vomiting 0 1 0
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the present study was conducted in a small study popula-
tion of healthy individuals, using only a single dose, and
should be interpreted in light of this. In addition, our
observations might not be extrapolated to elderly partici-
pants, or those with reduced renal function, as data have
shown that age-related changes in renal function can alter
the pharmacokinetics of gabapentin [31, 32].
5 Conclusions
The pharmacokinetic properties of gabapentin 500 mg and
zolpidem tartrate 10 mg are unaffected when both treat-
ments are taken simultaneously, compared with each treat-
ment taken alone. All treatments were well tolerated when
taken alone or in combination in this study population.
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